Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SVRA 
Savara Inc (SVRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: SVRA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.06
1 Year Target Price $7.06
| 4 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.31% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 378.51M USD | Price to earnings Ratio - | 1Y Target Price 7.06 |
Price to earnings Ratio - | 1Y Target Price 7.06 | ||
Volume (30-day avg) 8 | Beta 0.32 | 52 Weeks Range 1.89 - 5.11 | Updated Date 07/4/2025 |
52 Weeks Range 1.89 - 5.11 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.49 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.97% | Return on Equity (TTM) -75.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 235657859 | Price to Sales(TTM) 131146 |
Enterprise Value 235657859 | Price to Sales(TTM) 131146 | ||
Enterprise Value to Revenue 11.91 | Enterprise Value to EBITDA -4.76 | Shares Outstanding 172836992 | Shares Floating 86692653 |
Shares Outstanding 172836992 | Shares Floating 86692653 | ||
Percent Insiders 5.38 | Percent Institutions 98.53 |
Upturn AI SWOT
Savara Inc
Company Overview
History and Background
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Founded in 2011, the company has focused on developing innovative therapies for unmet medical needs in the pulmonology space.
Core Business Areas
- Molgramostim Nebulizer Solution: Savara's primary focus is on the development and potential commercialization of Molgramostim Nebulizer Solution, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for autoimmune pulmonary alveolar proteinosis (aPAP).
Leadership and Structure
Matt Pauls serves as the Chief Executive Officer. The company operates with a typical organizational structure for a biotech firm, including research and development, clinical operations, and commercial planning departments.
Top Products and Market Share
Key Offerings
- Molgramostim Nebulizer Solution: Molgramostim is Savara's lead product candidate targeting aPAP. The company is seeking regulatory approval in key markets. Market share data is prospective, dependent on regulatory approval and commercial success. Competitors include standard-of-care whole lung lavage (WLL).
Market Dynamics
Industry Overview
The rare respiratory disease market is characterized by high unmet medical needs and limited treatment options. The market offers opportunities for companies developing innovative therapies that can address specific patient populations.
Positioning
Savara is positioning itself as a leader in the rare respiratory disease space, specifically targeting aPAP with molgramostim. Their competitive advantage relies on positive clinical trial outcomes and successful regulatory approval.
Total Addressable Market (TAM)
The estimated TAM for aPAP is substantial, considering the lack of effective treatments. Savara aims to capture a significant portion of this market with molgramostim, assuming positive clinical data and regulatory approval.
Upturn SWOT Analysis
Strengths
- Lead product candidate with potential to address a significant unmet need
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on a single product candidate
- Clinical trial risk
- Regulatory approval risk
- Commercialization risk
- Limited revenue generation to date
Opportunities
- Potential for regulatory approval in multiple markets
- Expansion into other indications for molgramostim
- Strategic partnerships or acquisitions
- Further development of pipeline
Threats
- Competition from other companies developing therapies for aPAP
- Unfavorable clinical trial results
- Regulatory setbacks
- Market access challenges
- Patent challenges
Competitors and Market Share
Key Competitors
Competitive Landscape
Since SVRA does not yet have FDA approval and revenue, marketshare will be zero.
Growth Trajectory and Initiatives
Historical Growth: Savara's historical growth has been primarily driven by clinical development milestones.
Future Projections: Future growth is heavily dependent on the successful development and commercialization of molgramostim and its pipeline.
Recent Initiatives: Recent initiatives include completing clinical trials for molgramostim and preparing for potential regulatory submissions.
Summary
Savara is a clinical-stage company focused on a rare respiratory disease. Its success hinges on the approval and commercialization of its lead drug candidate. While the unmet need in aPAP represents a significant opportunity, the company faces inherent risks associated with clinical trials and regulatory approval. The company's financial performance depends on raising capital to fund its operations until revenue is generated. Overall, Savara's future is tied to the success of its clinical programs and market access strategies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Savara Inc. SEC Filings (10-K, 10-Q)
- Savara Inc. Investor Relations
- Company announcements and press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share information is based on estimates and projections and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Savara Inc
Exchange NASDAQ | Headquaters Langhorne, PA, United States | ||
IPO Launch date 2017-06-01 | Chairman & CEO Mr. Matthew Pauls J.D., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://www.savarapharma.com |
Full time employees 59 | Website https://www.savarapharma.com | ||
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.